Printer Friendly

'See Your Dentist - It Can Save Your Life,' Says Zila Pharmaceuticals, Inc., Promoting Oral, Head and Neck Cancer Awareness Week, April 17-22.

PHOENIX, April 17 /PRNewswire/ -- During this year's Oral, Head and Neck Cancer Awareness Week, April 17-22, Zila Pharmaceuticals, Inc., manufacturer and marketer of the ViziLite(R) Plus Oral Lesion Identification and Marking System, urges everyone to see a dentist for a potentially life-saving oral cancer exam.

The annual Awareness Week began in 1998, when the Yul Brynner Head and Neck Cancer Foundation used it to focus on the disease that contributed to the death of Brynner, an acclaimed Broadway and Hollywood actor. In anticipation of his death, Brynner made a television commercial in which he said, "Now that I'm gone, I tell you: Don't smoke, whatever you do, just don't smoke." That public service announcement remains one of the most memorable antismoking statements ever made.

Recently reported American Cancer Society (ACS) data show that despite an overall reduction in cancer deaths, oral cancer incidence and related deaths are increasing. The American Dental Association advises that while most cases of oral cancer affect people who use tobacco and/or drink heavily, more than a quarter of oral cancers occur in people who do not smoke and have no other risk factors.

According to ACS projections for 2006, oral cancer is the eighth most common cancer type among men, with a 10-year survival rate of less than 50%, primarily due to late detection. Some 67% of oral cancer lesions identified with conventional visual methods are detected late, leading to disfigurement and a high mortality rate. When oral cancer is detected early, the survival rate rises to nearly 90%. The key to successful treatment is early detection. Age is a primary risk factor; those 40 and older are at high risk.

ViziLite(R) Plus with TBlue630, A Potentially Life-Saving Technology

ViziLite Plus combines the oral screening technology of ViziLite, an advanced biophotonic light technology, with TBlue630, a marking system using Zila(R) Tolonium Chloride (ZTC(TM)), the only patented pharmaceutical-grade form of toluidine blue used in marking lesions identified during a ViziLite examination.

ViziLite Plus is indicated for use in individuals at increased risk for oral cancer. If ViziLite reveals an abnormality, TBlue630 may be used to mark suspicious lesions for further evaluation. Annual ViziLite Plus examinations, following the conventional head and neck examination, are recommended for all adult patients. The procedure is now covered by insurance for some patients.

"America's dentists and hygienists are performing heroic acts every day," said Dave Barshis, Zila Pharmaceuticals Vice President and General Manager. "They're putting a new light on oral cancer, and saving lives with early detection of this killer disease and its pre-cancer warning signs. During Oral, Head and Neck Cancer Awareness Week, we urge everyone to see their dentist for a comprehensive screening exam that includes ViziLite Plus."

About Zila Pharmaceuticals, Inc.

Zila Pharmaceuticals, Inc., a division of Zila, Inc. headquartered in Phoenix, is the marketer of products to promote oral health and prevent oral disease, including ViziLite(R) Plus Oral Lesion Identification and marking System and Peridex(R) prescription periodontal rinse.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2005.

CONTACT: Andrew Stevens, 602-266-6700, for Zila Pharmaceuticals, Inc.; or Public Relations, Bill Sklar of Sklar & Associates, +1-520-299-2830, for Zila Pharmaceuticals, Inc.
COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 17, 2006
Words:677
Previous Article:CSX Corporation to Hold First-Quarter 2006 Earnings Call on April 19, 2006.
Next Article:Xavier Frapaise, M.D., to Join Ocera Therapeutics, Inc., as Chief Medical Officer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters